Xencor Inc
XNCR7.900USD
-0.080-1.00%
Market hours （ET）Quotes delayed by 15 min
561.97MMarket Cap
LossP/E TTM
More Details of Xencor Inc Company
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Company Info
Ticker SymbolXNCR
Company nameXencor Inc
IPO dateDec 03, 2013
CEODr. Bassil I. Dahiyat, Ph.D.
Number of employees250
Security typeOrdinary Share
Fiscal year-endDec 03
Address465 N. Halstead St.
CityPASADENA
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code91107
Phone16263055900
Websitehttps://xencor.com/
Ticker SymbolXNCR
IPO dateDec 03, 2013
CEODr. Bassil I. Dahiyat, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
212.96K
+10.45%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
50.68K
+47.02%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
33.17K
-10.16%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
14.20K
+305.17%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
13.69K
--
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
13.20K
+427.04%
Dr. Kevin C. Gorman, Ph.D.
Dr. Kevin C. Gorman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Dr. A. Bruce Montgomery, M.D.
Dr. A. Bruce Montgomery, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Ellen Gwen Feigal, M.D.
Dr. Ellen Gwen Feigal, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
212.96K
+10.45%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
50.68K
+47.02%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
33.17K
-10.16%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
14.20K
+305.17%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
13.69K
--
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
13.20K
+427.04%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Royalties
18.23M
55.70%
Milestone
14.50M
44.30%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Royalties
18.23M
55.70%
Milestone
14.50M
44.30%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
15.09%
PRIMECAP Management Company
13.71%
The Vanguard Group, Inc.
12.12%
EcoR1 Capital, LLC
8.63%
T. Rowe Price Associates, Inc.
5.38%
Other
45.06%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
15.09%
PRIMECAP Management Company
13.71%
The Vanguard Group, Inc.
12.12%
EcoR1 Capital, LLC
8.63%
T. Rowe Price Associates, Inc.
5.38%
Other
45.06%
Shareholder Types
Shareholders
Proportion
Investment Advisor
59.58%
Investment Advisor/Hedge Fund
31.25%
Hedge Fund
15.77%
Research Firm
2.93%
Venture Capital
1.94%
Individual Investor
1.32%
Pension Fund
1.03%
Bank and Trust
0.36%
Sovereign Wealth Fund
0.25%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
437
81.46M
114.46%
-1.77M
2025Q1
459
80.70M
113.40%
-3.00M
2024Q4
454
76.54M
108.64%
-2.55M
2024Q3
455
73.66M
105.55%
+3.66M
2024Q2
436
65.64M
106.20%
-4.06M
2024Q1
431
66.91M
108.52%
-498.74K
2023Q4
420
65.39M
107.20%
-1.62M
2023Q3
417
65.14M
107.37%
-1.33M
2023Q2
422
64.91M
107.12%
-2.55M
2023Q1
418
65.89M
109.12%
+515.07K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
10.74M
15.09%
-230.83K
-2.10%
Mar 31, 2025
PRIMECAP Management Company
9.76M
13.71%
+776.58K
+8.64%
Mar 31, 2025
The Vanguard Group, Inc.
7.88M
11.08%
-118.90K
-1.49%
Mar 31, 2025
EcoR1 Capital, LLC
6.14M
8.63%
--
--
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.83M
5.38%
-108.25K
-2.75%
Mar 31, 2025
State Street Global Advisors (US)
3.68M
5.18%
+482.80K
+15.08%
Mar 31, 2025
BVF Partners L.P.
2.74M
3.85%
+451.38K
+19.72%
Mar 31, 2025
TCG Crossover Management, LLC
2.45M
3.45%
--
--
Mar 31, 2025
RTW Investments L.P.
2.40M
3.38%
--
--
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.74M
2.44%
+235.86K
+15.71%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
1.21%
Virtus LifeSci Biotech Clinical Trials ETF
0.75%
Invesco NASDAQ Future Gen 200 ETF
0.44%
Invesco S&P SmallCap Health Care ETF
0.4%
ALPS Medical Breakthroughs ETF
0.38%
SPDR S&P Biotech ETF
0.18%
Inspire Small/Mid Cap ESG ETF
0.14%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.08%
Invesco Nasdaq Biotechnology ETF
0.06%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion1.21%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.75%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.44%
Invesco S&P SmallCap Health Care ETF
Proportion0.4%
ALPS Medical Breakthroughs ETF
Proportion0.38%
SPDR S&P Biotech ETF
Proportion0.18%
Inspire Small/Mid Cap ESG ETF
Proportion0.14%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.1%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proportion0.08%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
